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Summary Antibodies against the glutamate receptor type 3–—(GluR3) have been
found in association with Rasmussen’s encephalitis (RE) but were also detected in
patients with non-inflammatory focal epilepsies. We report the case of an 18-year-old
patient with treatment refractory left mesial temporal lobe epilepsy accompanied by
high levels of GluR3 antibodies. Different from experiences in patients with RE
immunomodulatory therapy by use of intravenous gammaglobulines neither altered
GluR3 serum levels nor had any effect on seizure frequency in our patient. Interest-
ingly, GluR3 serum levels remained positive after successful surgical intervention
leading to patient’s seizure freedom.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
The pathogenic role of humoral or cellular autoim-
mune mechanisms for the development of epileptic
seizures is not well understood.1 Strongest evidence
for a direct involvement of the immune system in
epileptogenesis has been found in Rasmussen’s
encephalitis (RE), a rare condition presenting with* Corresponding author. Tel.: +43 316 385 80384;
fax: +43 316 385 3895.
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(M. Feichtinger).
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brain dysfunction and inflammatory histopathologi-
cal changes which may be accompanied by antibo-
dies against the ionotrophic glutamate receptor
(GluR3).2 Therapeutic concepts of this rare syn-
drome include — besides early resective surgery —
plasma exchange, immunosuppressive drugs, and
immunomodulation using intravenous administra-
tion of high-dose gammaglobulines (IVIG).3,4
Recently, it was reported that GluR3 antibodies
were non-specific for RE as they were also found in
some sera of patients with focal epilepsies.5,6 It
has, therefore, been speculated that — similar to. Published by Elsevier Ltd. All rights reserved.
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seizures in severe focal epilepsies, too. Different
pathogenetic mechanisms of these antibodies are
discussed: on the one hand, they may have an
excitotoxic glutamate-like potential as they were
shown to induce glutamate receptor like ion cur-
rents.7 On the other hand, GluR3 antibodies were
described to possess a neuronal-killing potential via
complement-dependent cytotoxicity mechanisms.8
As IVIG therapy is reported to be an effective
therapeutic regimen for patients with RE it may be
speculated that it has then also positive effects on
seizure frequency in patients with severe focal
epilepsy that are associated with positive GluR3
antibodies. Recently, in one child a short-lasting
IVIG therapy was ineffective.9 In this report we
present another patient (with focal temporal lobe
epilepsy and highly positive GluR3 antibodies) who
was treated with IVIG over 3 months.Figure 1 Coronal T2-weighted MRT image of the patient
with gyral atrophy of the left frontal, parietal and tem-
poral cortex as well as left hippocampal volume loss.Case report
The patient is an 18-year-old left-handed man
whose delivery was prolonged and complicated
(rupture of the uterus, Apgar score 3/6/9). His
subsequent psychomotor development was normal
and no neurological deficits were apparent. The
family history was negative for epilepsy and other
neurological disorders. At age 15, several weeks
after an antibiotic treatment of a sinusitis, he
developed short-lasting complex partial seizures
(CPS) with an initial perception of fear, oral auto-
matisms, speech arrest, a left-sided piloerection
and a loss of consciousness. Over the next few
months, the frequency of these focal seizures
increased–—in some periods up to 30—50 CPS/day.
Response to various combinations of high-dose car-
bamazepine, valproic acid, phenytoin, clonazepam
and levetiracetam was poor.Figure 2 Ictal 99Tc-m HMPAO scan (coronal slice) with focal t
the left basal ganglia (white arrow).Repeated electroencephalograms revealed fre-
quent interictal spikes over the left temporal
region. Ictal EEG during video-EEG monitoring
showed focal rhythmic spike-wave discharges in
the left temporal and frontal electrodes (F7, F3,
T5, T7, and TP9). MRI showed a diffuse atrophy of
the entire left hemisphere including the hippocam-
pal formation (see Fig. 1) with no apparent progres-
sion over 6 months. An ictal 99Tc-m HMPAO-SPECT
scan demonstrated a focally restricted increase of
tracer uptake in the left temporo-mesial region (see
Fig. 2). Neuropsychological testing revealed signifi-
cant deficits in the verbal memory compared to theracer enhancement in the left mesio-temporal region and
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Figure 3 Time course of serum reactivity against GluR3B1-peptide. ELISA optical densities (OD) with patient sera at
dilution of 1:10 are reported. Titers of the patient (i) before; (ii) after three monthly cycles of intravenous therapy with
gammaglobulines (IVIG); and (iii) 6 months after successful surgery (seizure freedom) are represented as OD values (grey
bars) for GluR3B1 reactivity. Note that titers remain elevated after IVIG therapy and successful surgery. Black bar (left)
shows in comparison the cut-off value for positivity (mean normal controls  3 S.D., black bar).visual memory and a bilateral language representa-
tion (WADA test).
Due to the clinical symptomatology with a high
seizure frequency up to occasional series of CPS over
days and the left hemispheric atrophy, RE was con-
sidered as differential diagnosis of focal temporal
epilepsy. CSF contained 1 lymphocyte/mm3, had no
oligoclonal bands, and total protein and glucose
were normal. The patient’s serum was investigated
for antibodies against glutamate receptors type 3
(GluR3) which were highly positive (for details see
below).
Although a defined epileptic focus within the left
mesio-temporal region could be found, the patient
was sceptical concerning a surgical procedure. A
high-dose IVIG therapy was started which consisted
of three monthly cycles (0.4 g/kg/day each month
over 5 days). Seizure frequency was completely
unaffected by this regimen. The patient, therefore,
consented to undergo left-sided partial lobectomy
(including amygdalo-hippocampectomy) and histo-
logical analysis for reliable exclusion of RE was
available. The histopathological specimen showed
no inflammatory process indicative of RE but signs of
a cortical dysplasia with heterotopic cells in the
white matter. Postoperatively, the patient was sei-
zure free with a follow-up period of 2 years now
(Engel class I A). Both, after the end of IVIG therapy
(three monthly cycles) as well as 6 months after
surgery, the patient’s serum was controlled for
levels of GluR3 antibodies. GluR3 antibody titers
including the epitope recognition pattern of the
complete GluR3 sequence6 remained unchanged
over time (see Fig. 3).GluR3 peptides and anti-GluR3-
antibody-ELISA
Different immunodominant regions of the GluR3-
receptor (GluR3A1, GluR3A2, GluR3B1, GluR3B2,N-terminal, hydrophilic domain, cytoplasmic
domain, and C-terminal) were chosen for testing
antibody reactivities.6 ELISA for the detection of
peptide-specific GluR3 antibodies was performed
as described previously.6 Fig. 3 shows the time
course of antibody reactivities against GluR3B1.
Optical density (OD) values were 2.343 before
and 2.290 after IVIG therapy, and 2.384 six
months after surgery. The cut-off for anti-GluR3B1
positivity (0.895 OD) was defined as mean OD  3
S.D. of the controls (‘‘CNS-normal’’ and healthy
donors: 0.419  0.476) as described recently.6
Of note, the patient exhibited strong reactivi-
ties also against other peptides of the GluR3-
receptor including the cytoplasmic domain.
Neither absolute values nor the recognition pat-
tern of the antibodies changed over time (data not
shown).Discussion
Concerning the clinical course and the therapy of
our patient three observations are remarkable.
First, the presence of GluR3 in the serum without
histopathological proof of RE corroborates recent
work reporting that these antibodies are non-spe-
cific for RE.5,6 Although the clinical picture of the
epileptic seizures did not resemble epilepsia partia-
lis continua and neurological deficits were not pro-
minent in our patient, the frequent series of CPS of
temporal origin were reminiscent of RE–—the more
so as there is some evidence in the literature for a
possible onset of the inflammatory process of RE in
the temporal lobe.10 The most likely underlying
cause of the development of seizures in our patient,
however, is a cortical migration disorder (based on
the histopathological analysis). According to the
patient’s history and the cranial MRT an additional
diffuse left hemispheric perinatal hypoxic damage
may be responsible for the seizures too, but this
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inflammatory signs were detectable histopathologi-
cally and repeated MRI scans showed no progressive
disorder. The high seizure frequency in RE and in
focal epilepsies accompanied by positive GluR3 anti-
bodies is commonly viewed as a result of an initial
blood-brain barrier disruption–—caused by different
possible mechanisms (e.g. trauma, seizure).11 This
allows circulating antibodies to enter into the brain
producing further neuronal injuries, subsequent sei-
zures and a constant focal blood-brain barrier dis-
ruption. This ‘‘vicious circle’’ leading to recurrent
seizures may be entertained by GluR3 antibodies–—
either via direct agonistic receptor activation7,12 or
by complement-dependent cytotoxicity mechan-
isms.8 Reports of clinical improvement in response
to elimination of GluR3 antibodies after plasma-
pheresis support the assumption of these autoanti-
bodies being causally involved in pathogenetic
process of RE.13 Whether a tendency to intractable
series of seizures in cryptogenic focal epilepsies
with elevated serum GluR3 levels could be provoked
by similar (auto) immune mechanisms remains spec-
ulative.
Secondly, in patients with RE seizures are
reported to decrease after therapy with IVIG4
but in our patient suffering from a cryptogenic
focal epilepsy this immunomodulatory treatment
showed no effect–—neither on seizure frequency
nor on GluR3 serum titers. This is consistent with
one recent case report9 of a child with focal epi-
lepsy and positive GluR3 autoantibodies. One rea-
son for the therapeutic failure of IVIG in both
patients may be that one single treatment cycle
in the child’s case9 and our 3 months treatment,
respectively, has been too short as in some patients
with RE improvements after immunomodulation
were also delayed.4 Due to multifaceted mechan-
isms, IVIG modulate mainly humoral but also cel-
lular immune responses.14 Possible mechanisms of
action that modulate humoral immune response
may be (i) neutralization of or competition with
the binding site of anti-GluR3 antibodies by anti-
idiotype antibodies; (ii) binding to complement
factors or reduction of activated complement
deposition with inhibition of complement-
mediated neuronal damage; and (iii) down regula-
tion of the production of GluR3 due to antibodies
against B cells. In our patient, GluR3 antibody
levels after IVIG therapy remained unchanged
arguing against the hypothesis of a suppressed
GluR3-production by B-cells following this treat-
ment strategy.
Our third observation of remaining high levels of
GluR3 antibodies 6 months after successful surgery
— despite of total cessation of seizures and withoutinterictal epileptic discharges on scalp EEG — was
surprising. If GluR3 antibodies were causally
involved in the epileptogenesis and their synthesis
thus be triggered by recurrent seizures and neuronal
damage, one would expect a decrease of antibody
titers in the absence of the triggering focus. Remain-
ing high levels of GluR3 antibodies may therefore be
rather interpreted as an unspecific (epi-) phenom-
enon in a subset of non-inflammatory focal epilepsy
patients with rather stable levels–—independent
from seizure frequency.
The current case provides insight on the effect
of immunomodulatory IVIG therapy in GluR3 posi-
tive patients with non-inflammatory focal epi-
lepsy: (i) immunomodulatory IVIG therapy was
not beneficial in our patient but may have been
if it were offered longer than 3 months. (ii) GluR3
antibody titers were not correlated to seizure
frequency and remained consistently high despite
removal of the epileptic focus. In this case GluR3
antibodies are highly unlikely to represent a cau-
sative and therefore treatable factor of epilepto-
genesis. However, further studies are needed to
clarify the pathogenetic relevance of GluR3 in
patients with focal epilepsies and the use of
immune oriented treatment strategies in this sub-
group of patients.References
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